What infusion rate should be used for DNS (5% dextrose in 0.9% saline) in a patient on an insulin infusion to maintain blood glucose between 150–200 mg/dL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

DNS Infusion Rate During Insulin Therapy

When a patient is on an insulin infusion and requires dextrose-containing fluids to maintain blood glucose between 150-200 mg/dL, start DNS (D5NS) alongside the insulin infusion at a rate that prevents hypoglycemia while maintaining target glucose levels. Based on the most recent 2025 ADA guidelines, this typically means initiating dextrose-containing fluids when glucose approaches the lower end of your target range 1.

Practical Approach to DNS Rate

The infusion rate should be titrated based on glucose monitoring every 1-2 hours, with typical starting rates around 75-125 mL/hr of D5NS (providing approximately 4-6 grams of dextrose per hour). This translates to roughly 0.5-1 mL/min of 5% dextrose solution 2.

Key Principles:

  • During active insulin infusion: The 2025 ADA guidelines specifically state that when glucose drops toward target range during DKA/HHS management, dextrose-containing fluids should be started alongside continued insulin infusion to maintain glucose between 150-200 mg/dL until resolution 1

  • Avoid hyperglycemia: Research shows that even 500 mL of D5NS can cause significant hyperglycemia (>10 mmol/L or 180 mg/dL) in 72% of patients 3. During active insulin infusion, this risk is mitigated, but rates still need careful titration

  • Perioperative considerations: Computer simulations suggest that during surgery and immediate postoperative period, glucose infusion rates should be reduced by 50-75% compared to baseline to avoid hyperglycemia - meaning no more than 0.5 mL/min (30 mL/hr) of D5 solution if strict normoglycemia is desired 2

Monitoring and Adjustment Algorithm

  1. Check glucose every 1-2 hours while on insulin infusion 4, 5

    • More frequent monitoring (every 15-30 minutes) may be needed during initial titration 6
  2. Adjust DNS rate based on glucose trend:

    • If glucose dropping toward 150 mg/dL: Increase DNS rate by 25-50 mL/hr
    • If glucose rising above 200 mg/dL: Decrease DNS rate by 25-50 mL/hr or increase insulin rate
    • If glucose stable 150-200 mg/dL: Continue current rate
  3. Typical DNS rates in practice:

    • Standard maintenance: 75-125 mL/hr of D5NS
    • Can provide up to 0.5 g/kg/hr of dextrose (approximately 35 g/hr or 700 mL/hr of D5NS for a 70 kg patient) 6
    • Most patients require much less than maximum rates

Critical Caveats

Never use DNS alone without insulin in hyperglycemic patients - this will worsen hyperglycemia. The dextrose is added specifically to prevent hypoglycemia while continuing necessary insulin therapy 1.

Avoid overly aggressive dextrose administration: The 2010 AHA guidelines for beta-blocker overdose (which also uses insulin-dextrose infusions) recommend 0.5 g/kg/hr of dextrose with very frequent glucose monitoring, but this is for a specific toxicologic indication 6. For routine glycemic management, lower rates are appropriate.

The half-life of glucose during insulin infusion is approximately 30 minutes, meaning glucose will continue to rise for another 25% after initiating or increasing DNS rate 2. Wait at least 1 hour before making further rate adjustments unless glucose is critically low.

In DKA/HHS specifically: The 2025 ADA guidelines emphasize that dextrose-containing fluids should be added when glucose reaches 200-250 mg/dL (for HHS) or 150-200 mg/dL (for DKA) to allow continued insulin administration until metabolic resolution 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.